PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
L. Vidarsdottir, A. Azimi, I. Sigvaldadottir, A. S. Rahmanto, A. Petri, S. Kauppinen, C. Ingvar, G. Jonsson, H. Olsson, M. Frostvik-Stolt, R. Tuominen, O. Sangfelt, K. Pokrovskaja, J. Hansson, D. Grander, , P. Johnsson
This study shows that PTENP1-AS contributes to BRAF inhibitor resistance and is linked to poor clinical outcomes in stage III melanoma.
bioRxiv · May 3, 2020Cancer Biology